Clinical Trials Logo

Down Syndrome clinical trials

View clinical trials related to Down Syndrome.

Filter by:

NCT ID: NCT05068570 Completed - Clinical trials for EFFECT OF ARM ERGOMETRY ON RESPIRATION

Effect of Arm Ergometry on Children With Down Syndrome

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

Cardiopulmonary issues are the major cause of sickness and hospitalisation in children with Down syndrome . Down syndrome children are also more likely to develop chronic lung infections, middle ear infections, and persistent tonsillitis.

NCT ID: NCT05024110 Completed - Clinical trials for Vitamin D Deficiency

Effect of Exercise Intensity on Vitamin D

Start date: January 25, 2021
Phase: N/A
Study type: Interventional

Children with Down's syndrome (DS) are more liable to vitamin D deficiency. Treating this deficiency with supplements is associated with the risk of intoxication due to increased intestinal absorption or decreased vitamin D metabolism. The aim of the study was to compare the effect of two exercise intensities on the modulation of vitamin D and Parathormone (PTH) levels in children with DS.

NCT ID: NCT05020366 Completed - Down Syndrome Clinical Trials

Preventing Obesity Through Parent Empowerment and the Activation of Routines (PrO-PEAR)

PrO-PEAR
Start date: October 4, 2021
Phase: N/A
Study type: Interventional

This study will examine the feasibility of the Preventing Obesity through Parent Empowerment and the Activation of Routines (PrO-PEAR) intervention using a open case-series for intervention optimization followed by a pilot RCT in which participants are randomized to receive PrO-PEAR or enhanced usual care (EUC). Specific aims include: 1. Optimize the PrO-PEAR intervention manual using an open case series with iterative stakeholder feedback. 2. To determine the feasibility of the PrO-PEAR intervention in terms of recruitment, randomization, retention, adherence, and acceptability. 3. Estimate the effects of the PrO-PEAR intervention on parent reported child health behaviors in each Institute of Medicine obesity prevention area (nutrition, physical activity, sedentary behavior, sleep) over time as compared to a control group. The following benchmarks will be used to determine feasibility: Recruitment: >3 parent/child dyads per month Retention: >75% of consented dyads will complete > 8 sessions Adherence: >80% clinician protocol adherence during 100% of sampled sessions Data Collection: >80% planned assessments collected among intervention completers. Acceptability: >90% of parent intervention completers rate intervention as acceptable. Additionally, it is predicted that parents will report greater gains in the areas of nutrition, sleep, sedentary behavior and physical activity in the PrO-PEAR group than those in the control group.

NCT ID: NCT05004337 Completed - Trisomy 21 Clinical Trials

Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies

VANISH
Start date: July 22, 2021
Phase:
Study type: Observational

The purpose of this study is to collect blood samples from women carrying a vanishing twin pregnancy to further develop Natera's non-invasive prenatal screening test to provide information about possible chromosomal conditions for the living twin

NCT ID: NCT04966403 Completed - Down Syndrome Clinical Trials

Effects of Stretch-shortening Cycle Exercises Postural Control in Down Syndrome

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

To investigate the effect of a 3-month, trampoline-based stretch-shortening cycle (SSC) exercises on muscle strength and postural control in children with Down syndrome.

NCT ID: NCT04818437 Completed - Down Syndrome Clinical Trials

Effect of Core Stability Exercises and Balance Training in Postural Control Among Down Syndrome

Start date: September 15, 2019
Phase: N/A
Study type: Interventional

Children with Down syndrome often present with problems of posture & balance and mobility. Balance training is an important component of physical activity interventions, with growing evidence that it can be beneficial for children with DS. Objective: To determine the effect core stability exercises and balance training in postural control among Down syndrome.

NCT ID: NCT04816409 Completed - Down Syndrome Clinical Trials

Effect of Neuro Developmental Therapy in Infants With Down Syndrome

Start date: March 15, 2019
Phase: N/A
Study type: Interventional

Neurodevelopmental treatments are a progressive therapeutic method experienced thru qualified therapists for the improvement in affected ones. The most important trial in Down syndrome children is motor milestones and postural reactions to develop on time. Neurodevelopmental therapy is applied to accurate atypical postural tone and to enable further regular motion for execution of presentation of abilities. Objective: To determine the effects of Neuro Developmental therapy in improving postural reaction and motor milestones in infants with Down syndrome.

NCT ID: NCT04787861 Completed - Down Syndrome Clinical Trials

Motorized Movement Therapy & Pulmonary Functions in Down Syndrome

Start date: December 17, 2018
Phase: N/A
Study type: Interventional

To investigate the effects of the addition of motorized movement therapy versus conventional chest physiotherapy alone on pulmonary functions, exercise capacity, and endurance in children with Down Syndrome

NCT ID: NCT04767412 Completed - Down Syndrome Clinical Trials

Inspiratory Muscle Training and Physical Fitness in Children With Down Syndrome Randomized Control Trial

Start date: September 3, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effect of inspiratory muscle training on physical fitness in Down syndrome children. Twenty Down syndrome children from both genders ranged in age chronologically from seven to ten years will be selected to participate in this study. Selection of the study sample and evaluation of physical fitness improvement as well as Inspiratory Muscle training will be conducted in the Down Syndrome Charitable Association (DSCA), Riyadh City. The study sample will be divided randomly into two equal groups of (A & B). All the children participated in the current study will receive 30 minutes of treatment session of aerobic exercise, group B will receive first 30 minutes of IMT then take a period time of rest about 30 minutes before starting the aerobic exercise. Exercise frequency three times per week for a period of three successive months. The Body mass index (BMI) of each participated child will be determined by measuring weight/ Kg and height/ m2 using Electronic weight and height scale to include BMI ≥ 29 Kg/ m2 to exclude the obese children. Also using Six Minute Walk Test (6MWT) for measuring the aerobic capacity and Pulse Oxymeter for measuring pulse rate and Oxygen saturation. In addition, The Gio Digital pressure gauge will be used to assess Respiratory Muscle Strength of children by determining the Maximal Inspiratory (MIP) and Expiratory Pressure (MEP) which used to detect the inspiratory training intensity and reflect the improvement in respiratory muscle strength after training program. Brockport Physical Fitness Test (BPFT) will be used to measure physical fitness of the participated children. The participated children will be assessed before and after three successive months . The obtained results of this study will measure Maximal Inspiratory (MIP) and Expiratory Pressure (MEP), Aerobic capacity, Musculoskeletal Function and Maximum Heart Rate (HR Max.) to determine the significant improvement of participated children

NCT ID: NCT04751136 Completed - Down Syndrome Clinical Trials

the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome

Start date: September 30, 2016
Phase: Phase 2
Study type: Interventional

Down syndrome is a genetic disorder that causes delay in both physical growth and mental development. It is the most frequently reported chromosomal abnormality and the most common genetic syndrome. Down syndrome is caused by trisomy of all or part of the genetic material of human chromosome 21. It is now estimated that 94% of individuals with Down syndrome have an extra chromosome 21 as a result of meiotic non-disjunction, or the abnormal segregation of chromosomes during maternal gamete formation and of the remaining 5%, less than 1% is due to somatic mosaicism and the rest is due to chromosome 21 translocations. The estimated incidence of Down syndrome is between 1 / 1,000 to 1 / 1,100 live births worldwide. In Egypt, the incidence of Down syndrome has been reported to be 1 / 1000 live births. Down syndrome is characterized by intellectual disability, short stature, distinctive facial characters and a number of co-morbidities including cardiac and digestive anomalies, thyroid problems, and childhood leukemia. Down syndrome infants will likely experience delays in certain areas and aspects of development. However, they will achieve all of the same milestones as other normal children, just on their own timetable. According to recent studies, the Down syndrome behavioral phenotype includes relative strengths in some aspects of visuo-spatial processing and social functioning as well as relative deficits in verbal processing. Language has been described as a "major area of deficit" in Down syndrome individuals with particular difficulties manifested in expressive language. Due to this high incidence of Down syndrome in Egypt and the associated co-morbidities, governmental care directed to this syndrome and other handicapping conditions has increased tremendously in the past few years to the extent that Down syndrome phenotype has become a phobia and many parents and/or physicians referred normal babies for karyotype due to either suspicion of chromosomal anomalies or just for reassurance of their parents. Although there has been enormous progress in the management of the physical aspects of Down syndrome e.g. repair of heart defects, little advancement has been made to prevent deterioration of cognitive function in these individuals. As a result, the dramatic increase in life expectancy of children with Down syndrome in the past few decades has not been paralleled with concurrent treatment for cognitive disabilities. Therefore, it has remained the most common cause of cognitive dysfunction in children. The pathogenesis of cognitive deficits and motor disabilities in Down syndrome individuals can be attributed to diminished number and size of neuronal density, progressive neuronal degeneration, impairment of neurogenesis, and reduction in dendrite formation as well as spine density which results in disruption of synaptic function and plasticity. Therefore, many of these individuals develop increasing problems with learning and memory in later life. Cerebrolysin® is a neurotrophic peptidergic mixture isolated from pig brain. It is produced by standardized enzymatic breakdown of lipid-free porcine brain proteins . It acts similar to endogenous neurotrophic factors in the form of promoting neuronal sprouting, stimulating neurogenesis, enhancing neuronal plasticity, and improving learning and memory. Several studies demonstrated that Cerebrolysin® can be used safely in the management of children with any of the following medical conditions: minimal cerebral dysfunction, resistant forms of nocturnal enuresis, neurosensory hypoacusis, attention deficit hyperkinetic disorder, autism and Asperger syndrome. The overall aim of the study is to assess the effect of Cerebrolysin® on neurocognitive development of infants with Down syndrome.